Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)
This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of P...
| Autores: | , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2009 |
| País: | Colombia |
| Institución: | Universidad del Rosario |
| Repositorio: | Repositorio EdocUR - U. Rosario |
| Idioma: | inglés |
| OAI Identifier: | oai:repository.urosario.edu.co:10336/23457 |
| Acceso en línea: | https://doi.org/10.1016/j.vaccine.2009.10.034 https://repository.urosario.edu.co/handle/10336/23457 |
| Access Level: | acceso abierto |
| Palabra clave: | Chloroquine Gamma interferon Interleukin 10 Interleukin 2 Interleukin 4 Interleukin 5 Malaria vaccine Primaquine Recombinant plasmodium vivax 34 antigen Recombinant protein Tumor necrosis factor alpha Unclassified drug Animal experiment Article Blood sampling Cytokine release Drug antigenicity Human Humoral immunity Immunogenicity Lymphocyte proliferation Molecular biology Monkey Nonhuman Nucleotide sequence Peripheral blood mononuclear cell Plasmodium vivax Plasmodium vivax malaria Priority journal Protein blood level Rabbit Adult Aged Animals Cytokines Haplorhini Humans Malaria vaccines Middle aged Protozoan proteins Rabbits Pf34 homologue Vaccine candidate indirect polyacrylamide gel western Blotting Electrophoresis Fluorescent antibody technique |
| Sumario: | This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria. © 2009 Elsevier Ltd. All rights reserved. |
|---|